Key Details
Price
$3.10Annual ROE
-12.27%Beta
1.37Events Calendar
Next earnings date:
Feb 20, 2025Recent quarterly earnings:
Nov 04, 2024Recent annual earnings:
Feb 20, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Allison Bratzel - Piper Sandler Andrea Tan - Goldman Sachs Srikripa Devarakonda - Truist Securities Evan Seigerman - BMO David Martin - Bloom Burton Brendan Smith - TD Securities Operator Good afternoon, and welcome to AbCellera's Q3 2024 Business Update Conference Call. My name is Tamiya, and I will facilitate the audio portion of today's interactive broadcast.
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago.
AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a little over $1B and is derisked based on comparable therapeutics. AbCellera is on track to submit ABCL575 for clinical trials in Q22025, helping the market reset its valuation on the company closer to the value of the lead asset.
AbCellera's Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company's net loss widened to $36.9 million due to increased R&D expenses. AbCellera's cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million.
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.11 per share a year ago.
Penny stocks represent an interesting investment opportunity.
The Baker brothers acquired millions of shares of AbCellera Biologics and Fate Therapeutics during the first months of 2024. AbCellera Biologics is a drug discovery business with a hand in more than a dozen experimental drugs in clinical-stage development.
AbCellera Biologics (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AbCellera Biologics is a biotechnology company built to discover new antibodies for other drugmakers. The stock has fallen more than 90% from its all-time high and by 57% from a peak it set last summer.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time) KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time) Live audio webcasts of each presentation may be accesse.
FAQ
- What is the primary business of AbCellera Biologics?
- What is the ticker symbol for AbCellera Biologics?
- Does AbCellera Biologics pay dividends?
- What sector is AbCellera Biologics in?
- What industry is AbCellera Biologics in?
- What country is AbCellera Biologics based in?
- When did AbCellera Biologics go public?
- Is AbCellera Biologics in the S&P 500?
- Is AbCellera Biologics in the NASDAQ 100?
- Is AbCellera Biologics in the Dow Jones?
- When was AbCellera Biologics's last earnings report?
- When does AbCellera Biologics report earnings?
- Should I buy AbCellera Biologics stock now?